

Supplementary Material

Facile synthesis of tetrasaccharide fragments of bioactive Asterosaponins novaeguinosides I and II from starfish *Culcita novaeguineae*

Geeta Karki^{ab} and Pintu Kumar Mandal^{ab*}



^aMedicinal and Process Chemistry Division, CSIR-Central Drug Research Institute, BS-10/1, Sector 10, Jankipuram extension, Sitapur Road, P.O. Box 173, Lucknow, 226031, India.

^bAcademy of Scientific and Innovative Research, New Delhi 110001, India



* Corresponding author; Email: pintuchem06@gmail.com

Table of Contents



- | | |
|---|----|
| 1. 1D and 2D NMR spectra of compounds 1,2,3, 7,12, 14-20 | S2 |
|---|----|





^1H and ^{13}C NMR spectra of *p*-Methoxyphenyl (6-deoxy- β -D-galactopyranosyl)-(1 \rightarrow 4)-(6-deoxy- β -D-glucopyranosyl)-(1 \rightarrow 2)-(6-deoxy- β -D-glucopyranosyl)-(1 \rightarrow 3)- α -D-glucopyranoside (**1**) (D_2O).





^{13}C DEPT 135 NMR and 2D COSY spectra of *p*-Methoxyphenyl (6-deoxy- β -D-galactopyranosyl)-(1 \rightarrow 4)-(6-deoxy- β -D-glucopyranosyl)-(1 \rightarrow 2)-(6-deoxy- β -D-glucopyranosyl)-(1 \rightarrow 3)- α -D-glucopyranoside (**1**) (D_2O).




2D HSQC (selected region) and HRMS of *p*-Methoxyphenyl (6-deoxy- β -D-galactopyranosyl)-(1 \rightarrow 4)-(6-deoxy- β -D-glucopyranosyl)-(1 \rightarrow 2)-(6-deoxy- β -D-glucopyranosyl)-(1 \rightarrow 3)- α -D-glucopyranoside (**1**) (D₂O).






^1H and ^{13}C NMR spectra of *p*-Methoxyphenyl (β -L-arabinopyranosyl)-(1 \rightarrow 4)-(6-deoxy- β -D-glucopyranosyl)-(1 \rightarrow 2)-(6-deoxy- β -D-glucopyranosyl)-(1 \rightarrow 3)- α -D-glucopyranoside (**2**) (D_2O).




2D COSY and 2D HSQC (selected region) of *p*-Methoxyphenyl (β -L-arabinopyranosyl)-(1 \rightarrow 4)-(6-deoxy- β -D-glucopyranosyl)-(1 \rightarrow 2)-(6-deoxy- β -D-glucopyranosyl)-(1 \rightarrow 3)- α -D-glucopyranoside (**2**) (D_2O).




HRMS of *p*-Methoxyphenyl (β -L-arabinopyranosyl)-(1 \rightarrow 4)-(6-deoxy- β -D glucopyranosyl)-(1 \rightarrow 2)-(6-deoxy- β -D-glucopyranosyl)-(1 \rightarrow 3)- α -D-glucopyranoside (**2**) (D₂O).





¹H, ¹³C and DEPT 135 NMR spectra of *p*-Methoxyphenyl-2,4,6-tri-*O*-benzyl- α -D-glucopyranoside (3) (CDCl₃).




¹H, ¹³C and DEPT 135 NMR spectra of ethyl-3,4-di-*O*-acetyl-2-*O*-chloroacetyl 1-thio-β-L-arabinopyranoside (7) (CDCl₃).




¹H, ¹³C and DEPT 135 NMR spectra of *p*-Methoxyphenyl-2,4,6-tri-*O*-benzyl-3-*O*-allyl- α -D-glucopyranoside (**12**) (CDCl₃).




^1H and ^{13}C NMR spectra of *p*-Methoxyphenyl (2-*O*-acetyl-3-*O*-benzyl-4,6-*O*-benzylidene- β -D-glucopyranosyl)-(1 \rightarrow 3)-2,4,6-tri-*O*-benzyl- α -D-glucopyranoside (**14**) (CDCl_3).





¹³C DEPT 135 NMR and 2D HSQC (selected region) of *p*-Methoxyphenyl (2-*O*-acetyl-3-*O*-benzyl-4,6-*O*-benzylidene-β-*D* glucopyranosyl)-(1→3)-2,4,6-tri-*O*-benzyl-α-*D*-glucopyranoside (**14**) (CDCl₃).




^1H , ^{13}C NMR and 2D HSQC (selected region) of *p*-Methoxyphenyl (3-*O*-benzyl-4,6-*O*-benzylidene- β -D-glucopyranosyl)-(1 \rightarrow 3)-2,4,6-tri-*O*-benzyl- α -D-glucopyranoside (**15**) (CDCl_3).




¹H, ¹³C and DEPT 135 NMR spectra of *p*-Methoxyphenyl (2,4-di-*O*-acetyl-3-*O*-benzyl-6-deoxy-β-D-glucopyranosyl)-(1→2)-(3-*O*-benzyl-4,6-*O*-benzylidene-β-D-glucopyranosyl)-(1→3)-2,4,6-tri-*O*-benzyl-α-D-glucopyranoside (**16**) (CDCl₃).




2D COSY and HSQC NMR spectra (selected regions) of *p*-Methoxyphenyl (2,4-di-*O*-acetyl-3-*O*-benzyl-6-deoxy- β -D-glucopyranosyl)-(1 \rightarrow 2)-(3-*O*-benzyl-4,6-*O*-benzylidene- β -D-glucopyranosyl)-(1 \rightarrow 3)-2,4,6-tri-*O*-benzyl- α -D-glucopyranoside (**16**) (CDCl₃).





¹H, ¹³C and HSQC NMR spectra (selected regions) of *p*-Methoxyphenyl (2,3,4-tri-*O*-benzyl-6-deoxy-β-D-glucopyranosyl)-(1→2)-(3-*O*-benzyl-4,6-*O*-benzylidene-β-D-glucopyranosyl)-(1→3)-2,4,6-tri-*O*-benzyl-α-D-glucopyranoside (**17**) (CDCl₃).





¹H, ¹³C and HSQC NMR spectra (selected regions) of *p*-Methoxyphenyl (2,3,4-tri-*O*-benzyl-6-deoxy- β -D-glucopyranosyl)-(1 \rightarrow 2)-(3-*O*-benzyl-6-deoxy- β -D-glucopyranosyl)-(1 \rightarrow 3)-2,4,6-tri-*O*-benzyl- α -D-glucopyranoside (**18**) (CDCl₃).





^1H , ^{13}C and DEPT 135 NMR spectra of *p*-Methoxyphenyl (2,3,4-tri-*O*-acetyl -6-deoxy β -D-galactopyranosyl)-(1 \rightarrow 4)-(2,3,4-tri-*O*-benzyl-6-deoxy- β -D-glucopyranosyl)-(1 \rightarrow 2)-(3-*O*-benzyl-6-deoxy- β -D-glucopyranosyl)-(1 \rightarrow 3)-2,4,6-tri-*O*-benzyl- α -D-glucopyranoside (**19**) (CDCl_3).



2D COSY and HSQC NMR spectra (selected regions) of *p*-Methoxyphenyl (2,3,4-tri-*O*-acetyl-6-deoxy- β -D-galactopyranosyl)-(1 \rightarrow 4)-(2,3,4-tri-*O*-benzyl-6-deoxy- β -D-glucopyranosyl)-(1 \rightarrow 2)-(3-*O*-benzyl-6-deoxy- β -D-glucopyranosyl)-(1 \rightarrow 3)-2,4,6-tri-*O*-benzyl- α -D-glucopyranoside (**19**) (CDCl_3).



¹H and ¹³C NMR spectra of *p*-Methoxyphenyl (2-*O*-chloroacetyl-3,4-di-*O*-acetyl-β-L-arabinopyranosyl)-(1→4)-(2,3,4-tri-*O*-benzyl-6-deoxy-β-D-glucopyranosyl)-(1→2)-(3-*O*-benzyl-6-deoxy-β-D-glucopyranosyl)-(1→3)-2,4,6-tri-*O*-benzyl-α-D-glucopyranoside (**20**) (CDCl₃).



2D COSY and HSQC NMR spectra (selected regions) of *p*-Methoxyphenyl (2-*O*-chloroacetyl-3,4-di-*O*-acetyl- β -L-arabinopyranosyl)-(1 \rightarrow 4)-(2,3,4-tri-*O*-benzyl-6-deoxy- β -D-glucopyranosyl)-(1 \rightarrow 2)-(3-*O*-benzyl-6-deoxy- β -D-glucopyranosyl)-(1 \rightarrow 3)-2,4,6-tri-*O*-benzyl- α -D-glucopyranoside (**20**) (CDCl₃).